A global consensus statement on menopause hormone therapy – aims, aspirations and action points

Panay, Nick; Fenton, Anna

doi:10.3109/13697137.2013.772794

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Much controversy has ensued subsequent to the WHI reports; MHT is a Class 3 indication (i.e. contraindicated/not recommended) for primary or secondary prevention of cardiovascular disease 29 , while the North American Menopause Society, as well as the Global Consensus Statement on Menopausal Hormone Therapy, recommends MHT for women early in menopause with symptoms 28 , 30 . These results have the potential to provide needed and clinically relevant information regarding the use of MHT in postmenopausal women.…”

Section: Introductionmentioning

confidence: 99%

Endothelial function in women of the Kronos Early Estrogen Prevention Study

et al. 2015

View full text Add to dashboard Cite

ObjectiveEndothelial dysfunction occurs early in the atherosclerotic disease process, often preceding clinical symptoms. Use of menopausal hormone treatment (MHT) to reduce cardiovascular risk is controversial. This study evaluated effects of 4 years of MHT on endothelial function in healthy, recently menopausal women.MethodsEndothelial function was determined by pulse volume digital tonometry providing a reactive hyperemia index (RHI) in a subset of women enrolled in the Kronos Early Estrogen Prevention Study. RHI was measured before and annually after randomization to daily oral conjugated equine estrogen (oCEE, 0.45 mg), weekly transdermal 17β-estradiol (tE2, 50 μg) each with intermittent progesterone (200 mg daily 12 days of the month) or placebo pills and patch.ResultsAt baseline, RHI averaged 2.39 ± 0.69 (mean ± standard deviation; n = 83), and over follow-up did not differ significantly among groups: oCEE, 2.26 ± 0.48 (n = 26); tE2, 2.26 ± 0.45 (n = 24); and placebo, 2.37 ± 0.37 (n = 33). Changes in RHI did not correlate with changes in traditional cardiovascular risk factors, but may inversely correlate with carotid intima medial thickness (Spearman correlation coefficient ρ = −0.268, p = 0.012).ConclusionIn this 4-year prospective assessment of recently menopausal women, MHT did not significantly alter RHI when compared to placebo.

show abstract